Etanercept: Brands, Price & Uses in Bangladesh

Etanercept is a tumor necrosis factor (TNF)-alpha inhibitor (fusion protein biologic) indicated for the treatment of the following conditions:

Established / FDA-approved indications

• Rheumatoid arthritis (RA) in adults, to reduce signs and symptoms, induce major clinical response, inhibit progression of structural damage, and improve physical function. May be used alone or in combination with methotrexate.
• Polyarticular juvenile idiopathic arthritis (JIA) in patients aged 2 years and older.
• Psoriatic arthritis in adults, including use in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
• Ankylosing spondylitis in adults.
• Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, and in pediatric patients 4 years and older.

Combination therapy

Etanercept is commonly combined with methotrexate in rheumatoid arthritis and psoriatic arthritis for patients with an inadequate response to methotrexate monotherapy; this combination has demonstrated additional benefit over either agent alone.

Off-label / less-established uses

Etanercept is not FDA-approved for inflammatory bowel disease (Crohn's disease or ulcerative colitis) and is generally not recommended for these conditions due to lack of efficacy. Uveitis and other TNF-mediated conditions are used off-label in select cases only under specialist supervision; such use should be individualized and is not a standard indication.

Adult Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

Adult Plaque Psoriasis

50 mg subcutaneously twice weekly (administered 3–4 days apart) for 3 months, followed by a maintenance dose of 50 mg once weekly.

Pediatric Dosing

Administration

Etanercept is for subcutaneous injection only and is not for intravenous or intramuscular administration. Injection sites (thigh, abdomen, or upper arm) should be rotated, and new injections should be given at least 1 inch (2.5 cm) from an old site, avoiding areas that are tender, bruised, red, or hard. Patients or caregivers may self-administer after proper training. Missed doses should be taken as soon as remembered unless the next scheduled dose is due soon; doses should not be doubled.

Renal and Hepatic Impairment

No formal dose adjustment has been established for renal or hepatic impairment; Etanercept has not been extensively studied in these populations, so use with caution and clinical monitoring.

Common Side Effects

• Injection-site reactions (redness, itching, pain, or swelling) — most common, usually mild and self-limiting
• Upper respiratory tract infections (sinusitis, pharyngitis)
• Headache
• Mild allergic reactions (rash)

Serious Side Effects

• Serious infections, including tuberculosis reactivation, invasive fungal infections, and serious bacterial or viral infections (see Precautions and Warnings)
• Malignancies, including lymphoma and, rarely, hepatosplenic T-cell lymphoma (see Precautions and Warnings)
• New-onset or worsening heart failure
• Demyelinating disorders (new onset or exacerbation)
• Hepatitis B reactivation in chronic carriers
• Cytopenias (rare): leukopenia, neutropenia, thrombocytopenia, aplastic anemia
• Lupus-like syndrome (rare, generally reversible after discontinuation)
• Severe allergic/hypersensitivity reactions, including angioedema and anaphylaxis (rare)

Patients should seek prompt medical attention for signs of infection (fever, persistent cough, night sweats), unusual bruising/bleeding, unexplained fatigue, or symptoms of heart failure (shortness of breath, swelling of ankles/legs).